Overview
flowchart TD
companies_kaken_pharmaceutical["Kaken Pharmaceutical Co., Ltd."]
style companies_kaken_pharmaceutical fill:#4fc3f7,stroke:#333,color:#000
companies_kaken_phar_0["Company Overview"]
companies_kaken_pharmaceutical -->|"includes"| companies_kaken_phar_0
style companies_kaken_phar_0 fill:#81c784,stroke:#333,color:#000
companies_kaken_phar_1["Corporate History"]
companies_kaken_pharmaceutical -->|"includes"| companies_kaken_phar_1
style companies_kaken_phar_1 fill:#ef5350,stroke:#333,color:#000
companies_kaken_phar_2["Focus Areas"]
companies_kaken_pharmaceutical -->|"includes"| companies_kaken_phar_2
style companies_kaken_phar_2 fill:#ffd54f,stroke:#333,color:#000
companies_kaken_phar_3["Orthopedic Medications"]
companies_kaken_pharmaceutical -->|"includes"| companies_kaken_phar_3
style companies_kaken_phar_3 fill:#ce93d8,stroke:#333,color:#000
companies_kaken_phar_4["Dermatological Products"]
companies_kaken_pharmaceutical -->|"includes"| companies_kaken_phar_4
style companies_kaken_phar_4 fill:#4fc3f7,stroke:#333,color:#000
companies_kaken_phar_5["Central Nervous System CNS"]
companies_kaken_pharmaceutical -->|"includes"| companies_kaken_phar_5
style companies_kaken_phar_5 fill:#81c784,stroke:#333,color:#000
...
Overview
Mermaid diagram (expand to render)
Kaken Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4971) is a Tokyo-based pharmaceutical company with a focus on orthopedics, dermatology, and central nervous system disorders. The company has a long history in Japan dating back to 1948 and has developed several important CNS drugs["@kaken"].
Company Overview | Attribute | Details |Founded | 1948 |Headquarters | Tokyo, Japan |Stock | TSE Prime (4971) |Market Cap | Approximately ¥40-60 billion |Focus Areas | Orthopedics, Dermatology, CNS |
Corporate History
1948 : Founded as pharmaceutical manufacturer in Japan1960s : Expansion into orthopedic and dermatological products1980s : Development of CNS portfolio2000s : Strategic partnerships with international pharmaPresent : Diversified pharmaceutical company with CNS focusFocus Areas
Orthopedic Medications
Pain management for orthopedic conditions
Osteoporosis treatments
Anti-inflammatory agents
Dermatological Products
Topical treatments
Skin disease therapeutics
Central Nervous System (CNS)
[Neuropathic pain](/topics/neuropathic-pain-treatment) management
[Neuroinflammation](/mechanisms/neuroinflammation-pathways) research
[Alzheimer's disease](/diseases/alzheimers-disease) early-stage programs
Neurodegeneration Research
Neuropathic Pain Kaken has been involved in research related to:
Neuropathic pain : Development of treatments for chronic neuropathic pain conditionsPain modulation : Targeting pain signaling pathwaysPeripheral neuropathy : Diabetic neuropathy and other conditionsNeuroinflammation Research into anti-inflammatory approaches for CNS disorders:
[Microglia](/cell-types/microglia) modulation
Cytokine pathway inhibitors
Neuroprotective anti-inflammatory approaches
Alzheimer's Disease Early-stage research programs targeting:
[Amyloid-beta](/proteins/amyloid-beta) pathology
[Tau](/proteins/tau) aggregation
Neuroinflammation in AD
Parkinson's Disease
Research into dopaminergic therapies
Motor symptom management
Neuroprotection approaches
Key Products | Product | Indication | Category |
Research Pipeline | Program | Indication | Stage |
Partnerships and Collaborations
International Partnerships
Licensing agreements with international pharmaceutical companies
Distribution partnerships for Japanese market
Academic Collaborations
Collaborations with Japanese universities
Research partnerships with Japanese research institutions
Government Connections
Work with [PMDA](https://www.pmda.go.jp/) (Pharmaceuticals and Medical Devices Agency)
Compliance with [MHLW](https://www.mhlw.go.jp) regulations
Japanese Pharmaceutical Market Japan represents a significant market for pharmaceutical development:
Aging population : Growing elderly population increases demand for CNS therapiesRegulatory environment : PMDA provides robust regulatory frameworkResearch infrastructure : Strong academic and industry research capabilitiesMarket size : Third largest pharmaceutical market globallyCompetitive Landscape Kaken competes with major Japanese pharmaceutical companies:
Takeda Pharmaceutical
[Astellas Pharma](/companies/astellas)
[Daiichi Sankyo](/companies/daiichi-sankyo)
Eisai
Mitsubishi Tanabe Pharma
Strategic Position Kaken's position in the Japanese market:
Niche focus : Orthopedic and dermatological expertiseCNS expansion : Growing neuroscience portfolioPartnership model : Licensing and distribution agreementsDomestic strength : Strong Japan market presenceMarket Share | Therapeutic Area | Market Position |
Growth Strategy
Expand CNS portfolio : Develop novel CNS therapeuticsPartnership model : License international products for JapanAging population focus : Target CNS diseases affecting elderlyGeneric expansion : Develop generic versions of off-patent CNS drugs
Financial Overview
Revenue : ~¥50 billion (2024)R&D investment : ~15% of revenueOperating margin : ~10%Employees : ~2,500| Detail | Information |
Quality and Compliance Kaken maintains rigorous quality standards:
PMDA compliance : Fully compliant with Japanese pharmaceutical regulationsGMP certification : All facilities GMP-certifiedISO certifications : ISO 9001, ISO 14001Regular inspections : Both internal and regulatory auditsSee Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Neuropathic Pain Treatment](/topics/neuropathic-pain-treatment)
[Japanese Pharmaceutical Companies](/companies/japan-pharmaceutical-landscape)
[Neuroinflammation](/mechanisms/neuroinflammation-pathways)
[Amyloid-Beta](/proteins/amyloid-beta)
[Tau Protein](/proteins/tau)
References
[Kaken Pharmaceutical Official Website](https://www.kaken.co.jp/)
[Kaken Pharmaceutical - Bloomberg](https://www.bloomberg.com/companies/4971:jp)
[Japan Ministry of Health, Labour and Welfare](https://www.mhlw.go.jp) Show full description